Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia
- 242 Downloads
Purpose of Review
To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice.
CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Several prognostic scoring systems have been developed to risk stratify CMML patients. While all these models are valid, they demonstrate significant predictive heterogeneity.
Significant intra-patient (applying different models in the same patient giving rise to different prognostic results) and intra-model (patients in a similar prognostic group by a given model can be reclassified to different risk groups by other models) heterogeneities exist when applying current CMML prognostic models in the clinic. A personalized prediction approach may open new opportunities in risk stratifying patients with CMML and other myeloid malignancies.
KeywordsModels Prognosis CMML
Current publication is supported in part by grants from the “The Gerstner Family Career Development Award” and the Mayo Clinic Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NI.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746–54.CrossRefPubMedGoogle Scholar
- 13.•• Nazha A, Al-Issa K, Hamilton BK, et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31(12):2848–50. This is the first study to incorporate molecular data into four commonly used prognostic models in MDS and CMML.CrossRefPubMedGoogle Scholar
- 18.Nazha A, Seastone D, Keng M, et al. The revised international prognostic scoring system (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes. Leuk Lymphoma. 2015:1–12.Google Scholar
- 32.• Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7):e333. This study evaluated the prognostic impact of estachlised models in a large international cohort of CMML patients from seven US and European centers. CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Nazha A, Patnaik MM, Komrokji RS, et al. Model heterogeneity in predicting outcomes in patients with chronic myelomonocytic leukemia (CMML): an overestimation of survival in lower-risk group. Blood. 2017;130(Suppl 1):4255.Google Scholar